Compare Fortinet Inc (FTNT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Fortinet (FTNT) trades at $161.46, down 3.22% today, but maintains a bullish technical signal with strong moving averages and support near $162. The company reported consistent earnings beats, with Q1 2026 EPS of $0.82 surpassing the $0.619 estimate, and demonstrates robust fundamentals including 80.3% gross margins and 27.49% net income margin. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with Fortinet expanding its FortiEndpoint platform for AI security (GlobeNewsWire, July 14, 2026).

Outlook is positive due to AI cybersecurity tailwinds and earnings momentum, but high valuation ratios (P/E of 63.76, P/S of 17.5) pose risks if growth slows. Analyst consensus is mixed with 42.65% buy ratings, though the $123.16 price target suggests caution relative to current levels. Key risks include competitive pressures and reliance on enterprise IT spending cycles.

Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.

Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.